Hegade VS, Sood R, Saralaya D, Moreea S

Language: English
References: 22
Page: 461-465
PDF size: 379.11 Kb.

ABSTRACT

Pegylated interferon (Peg-IFN) in combination with ribavirin is the standard of care in the treatment of chronic hepatitis C (HCV). Peg-IFN is known to have a number of side effects but severe respiratory complications are uncommon. We report two cases, one of Peg-IFN induced interstitial pneumonitis (IP) and the other of bronchiolitis obliterans organising pneumonia (BOOP) in patients with chronic hepatitis C infection. In general, respiratory complications of Peg-IFN are mild and resolve with withdrawal of Peg-IFN. However, as illustrated in our first case fatal interstitial pneumonitis can occur. We present a review of the available literature on Peg-IFN induced lung toxicity. In conclusion, pulmonary toxicity with Peg-IFN is rare but fatality can occur. We highlight the importance of maintaining a high index of suspicion for early diagnosis and prompt treatment, which includes withdrawal of Peg-IFN and consideration of corticosteroid treatment.

REFERENCES

1. Hepatitis C in the UK: 2011 report, Health Protection Agency, www.hpa.org.uk. Accessed on 04.04.2012.

2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.

3. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 1017-21.

4. Midturi J, Sierra-Hoffman M, Hurley D, Winn R, Beissner R, Carpenter J. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature. Clin Infect Dis 2004; 39: 1724-9.

5. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002; 97: 2432-40.

6. Renou C, Germain S, Harafa A, Martin S, Larroque O, Muller P, Bertrand JJ, et al. Interstitial pneumonia recurrence during chronic hepatitis C treatment. Am J Gastroenterol 2005; 100: 1625-6.

7. Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M. Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 667-70.

8. Atug O, Akin H, Alahdab YO, Ceyhan B, Tozun N, Ozdogan O. Interstitial pneumonitis associated with pegylated interferon- alpha 2a and ribavirin for chronic hepatitis C infection: a case report. Cases J 2009; 10: 6464.

9. Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg) interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010; 55: 579-85.

10. Chen YC, Lu SN, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Chang Gung Med J 2007; 30: 92-7.

11. Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003; 124: 406-10.

12. Fuhrmann V, Kramer L, Bauer E, Laferl H, Tucek G, Dekan G, Schenk P. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection. Dig Dis Sci 2004; 49: 1966-70.

13. Carrillo-Esper R, González-Avila D, Uribe-Ríos M, Méndez- Sánchez N. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann Hepatol 2008; 7: 87-90.

14. Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M. Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol 2010; 16(35): 4394-9.

15. Hartman TE, Swensen SJ, Hansell DM, Colby TV, Myers JL, Tazelaar HD, Nicholson AG, et al. Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology 2000; 217: 701-5.

16. Trullas Vila JC, Padilla López DR, Bisbe Company V, Soler Simón S, Cortés Hausmann P, Bisbe Company J. Organizing pneumonia associated with the use of pegylated interferon alfa. Arch Bronconeumol 2008; 44: 173-4.

17. Jensen SP, Lynch DA, Brown KK, Wenzel SE, Newell JD. High-resolution CT features of severe asthma and bronchiolitis obliterans. Clin Radiol 2002; 57: 1078-85.

18. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez- Torres M, Flisiak R, Rasenack JW, et al. Albinterferon Alfa- 2b was not inferior to pegylated interferon-a in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139(4): 1267-76.

19. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez- Torres M, Bacon BR, Grigorescu M, et al. Albinterferon alfa-2b was not inferior to pegylated interferon-á in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology.2010; 139(4): 1257-66.

20. Pockros PJ. Why do we need another interferon? Gastroenterology 2010; 139(4): 1084-6.

21. Human Genome Sciences announces preliminary feedback from FDA on Zalbin BLA for chronic hepatitis C [press release]. Rockville, MD: Human Genome Sciences, Inc.; June 14, 2010.

22. Human Genome Sciences announces withdrawal of European Marketing Authorization Application for Jouferon® Zalbin™ for the treatment of chronic hepatitis C [press release]. Rockville, MD: Human Genome Sciences, Inc; April 19, 2010.